Management of Pain in Liver Disease
Medication Considerations
- Oxycodone should be avoided in patients with end-stage liver disease and used with caution in those with less severe hepatic impairment due to decreased clearance and increased risk of adverse effects, as recommended by the European Association for the Study of the Liver (EASL) 1
- Fentanyl is a preferred alternative because it does not produce toxic metabolites, has a stable blood concentration in cirrhosis, and is not dependent on renal function for elimination, according to the European Association for the Study of the Liver (EASL) 1
- Hydromorphone has a relatively stable half-life even in liver dysfunction and requires dose reduction but the interval can remain standard, as noted by the European Association for the Study of the Liver (EASL) 1
- In patients with hepatic impairment, closer clinical monitoring and opioid dose adjustment should be performed, starting with lower doses than usual and titrating carefully, with close monitoring for signs of respiratory depression, as recommended by the American College of Clinical Oncology 2
- Methadone should be used only by experienced physicians, as it is primarily excreted via the fecal route 2
- Caution should be exercised when using inhibitors of CYP3A4 (such as ritonavir), which can decrease fentanyl clearance by up to 67% 1
- Concomitant administration with benzodiazepines or gabapentinoids should be avoided, as it may increase the risk of sedation and respiratory depression 1
- For patients with renal impairment, careful titration and frequent monitoring are required when using oxycodone, and alternative opioids like methadone should be considered, while morphine, meperidine, codeine, and tramadol should be avoided 2
- The following opioids have specific metabolism and excretion characteristics: